Lamivudin var ikke genotoksisk in vivo ved doser, der medførte plasmakoncentrationer op til 30- 40 gange højere end kliniske plasmakoncentrationer.
Lamivudine has not shown any genotoxic activity in the in vivo studies at doses that gave plasma concentrations up to 30-40 times higher than clinical plasma concentrations.